These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 8622625)
1. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Skladanowski A; Plisov SY; Konopa J; Larsen AK Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625 [TBL] [Abstract][Full Text] [Related]
2. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Lelièvre S; Benchokroun Y; Larsen AK Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Berger B; Marquardt H; Westendorf J Cancer Res; 1996 May; 56(9):2094-104. PubMed ID: 8616856 [TBL] [Abstract][Full Text] [Related]
4. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Tanabe K; Ikegami Y; Ishida R; Andoh T Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204 [TBL] [Abstract][Full Text] [Related]
7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
8. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Poddevin B; Riou JF; Lavelle F; Pommier Y Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227 [TBL] [Abstract][Full Text] [Related]
9. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Morgan SE; Cadena RS; Raimondi SC; Beck WT Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639 [TBL] [Abstract][Full Text] [Related]
10. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II. Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662 [TBL] [Abstract][Full Text] [Related]
11. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Rowe TC; Chen GL; Hsiang YH; Liu LF Cancer Res; 1986 Apr; 46(4 Pt 2):2021-6. PubMed ID: 3004716 [TBL] [Abstract][Full Text] [Related]
12. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768 [TBL] [Abstract][Full Text] [Related]
13. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors. Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406 [TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies with cytotoxic anthrapyrazoles. Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398 [TBL] [Abstract][Full Text] [Related]
16. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol. Adlakha RC; Ashorn CL; Chan D; Zwelling LA Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251 [TBL] [Abstract][Full Text] [Related]
17. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987 [TBL] [Abstract][Full Text] [Related]
18. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Pommier Y; Schwartz RE; Zwelling LA; Kerrigan D; Mattern MR; Charcosset JY; Jacquemin-Sablon A; Kohn KW Cancer Res; 1986 Feb; 46(2):611-6. PubMed ID: 3000581 [TBL] [Abstract][Full Text] [Related]
19. Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors. Barrows LR; Radisky DC; Copp BR; Swaffar DS; Kramer RA; Warters RL; Ireland CM Anticancer Drug Des; 1993 Oct; 8(5):333-47. PubMed ID: 8251041 [TBL] [Abstract][Full Text] [Related]
20. Antitumor agents. Part 230: C4'-esters of GL-331 as cytotoxic agents and DNA topoisomerase II inhibitors. Han S; Xiao Z; Bastow KF; Lee KH Bioorg Med Chem Lett; 2004 Jun; 14(11):2979-82. PubMed ID: 15125972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]